Organization Overview
Alternative names
abemaciclib (verzenio) (1 trial)
abiraterone (zytiga) (3 trials)
anastrozole (arimidex) (4 trials)
apalutamide (erleada) (1 trial)
asparaginase (elspar) (1 trial)
atezolizumab (tecentriq) (3 trials)
autologous bone marrow (1 trial)
bacille calmette-guerin (1 trial)
bicalutamide (casodex) (3 trials)
bleomycin (blenoxane) (2 trials)
cabazitaxel (jevtana kit) (3 trials)
capecitabine (xeloda) (12 trials)
carboplatin (paraplatin) (7 trials)
cisplatin (platinol) (19 trials)
dacarbazine (dtic-dome) (1 trial)
daunorubicin (cerubidine) (1 trial)
docetaxel (taxotere) (18 trials)
doxorubicin (Doxil) (7 trials)
enzalutamide (xtandi) (1 trial)
epirubicin (ellence) (12 trials)
estramustine (emcyt) (1 trial)
etoposide (vepesid) (11 trials)
everolimus (zortress) (2 trials)
exemestane (aromasin) (4 trials)
filgrastim (neupogen) (1 trial)
fluorouracil (efudex) (42 trials)
flutamide (eulexin) (2 trials)
fulvestrant (faslodex) (5 trials)
gemcitabine (gemzar) (9 trials)
irinotecan (Camptosar) (17 trials)
ixabepilone (ixempra) (1 trial)
leuprolide (lupron) (4 trials)
levoleucovorin (fusilev) (1 trial)
mercaptopurine (purinethol) (1 trial)
methylprednisolone (medrol) (2 trials)
mitoxantrone (novantrone) (1 trial)
nilutamide (nilandron) (1 trial)
oxaliplatin (eloxatin) (24 trials)
pembrolizumab (keytruda) (4 trials)
peripheral blood hematopoietic cell (4 trials)
prednisone (meticorten) (3 trials)
procarbazine (matulane) (1 trial)
sacituzumab govitecan (1 trial)
sargramostim (leukine) (4 trials)
tamoxifen (nolvadex) (5 trials)
trastuzumab (herceptin) (5 trials)
triptorelin (Trelstar) (4 trials)
vinblastine (velban) (3 trials)
afatinib (gilotrif) (2 trials)
allogeneic hematopoietic stem cells (Hemacord) (1 trial)
allogeneic lymphocytes (1 trial)
bevacizumab (avastin) (9 trials)
binimetinib (mektovi) (1 trial)
cetuximab (erbitux) (8 trials)
copanlisib (aliqopa) (1 trial)
crizotinib (xalkori) (1 trial)
degarelix acetate (firmagon) (1 trial)
durvalumab (imfinzi) (8 trials)
encorafenib (braftovi) (1 trial)
fam-trastuzumab deruxtecan-nxki (Enhertu) (1 trial)
fludarabine (fludara) (1 trial)
hydroxyurea (hydrea) (1 trial)
idarubicin (idamycin) (1 trial)
interferon alpha-2b (Intron-A) (1 trial)
mitomycin (mutamycin) (2 trials)
muramyl tripeptide phosphatidyl ethanolamine (1 trial)
olaparib (lynparza) (2 trials)
palbociclib (ibrance) (3 trials)
pazopanib (votrient) (3 trials)
pertuzumab (perjeta) (2 trials)
pravastatin (pravachol) (1 trial)
Adenocarcinoma (Phase 3)
Anus Neoplasms (Phase 3)
Bile Duct Neoplasms (Phase 3)
Breakthrough Pain (Phase 2)
Breast Neoplasms (Phase 3)
Carcinoma (Phase 3)
Carcinoma, Ductal (Phase 2)
Carcinoma, Hepatocellular (Phase 2)
Carcinoma, Neuroendocrine (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 3)
Carcinoma, Renal Cell (Phase 2)
Carcinoma, Squamous Cell (Phase 2)
Carcinoma, Transitional Cell (Phase 3)
Central Nervous System Neoplasms (Phase 2)
Cholangiocarcinoma (Phase 3)
Chondroma (Phase 2)
Chondrosarcoma (Phase 2)
Choriocarcinoma (Phase 3)
Colonic Neoplasms (Phase 3)
Colorectal Neoplasms (Phase 3)
Depression (Phase 2)
Disease Progression (Phase 2)
Endodermal Sinus Tumor (Phase 3)
Endometrial Neoplasms (Phase 3)
Esophageal Neoplasms (Phase 3)
Fibroma (Phase 2)
Fibromatosis, Aggressive (Phase 2)
Gallbladder Neoplasms (Phase 3)
Gastrointestinal Stromal Tumors (Phase 3)
Germinoma (Phase 3)
Glioblastoma (Phase 2)
Head and Neck Neoplasms (Phase 2)
Hemangiosarcoma (Phase 2)
Hematologic Neoplasms (Phase 2)
Inflammatory Breast Neoplasms (Phase 3)
Kidney Neoplasms (Phase 2)
Leiomyosarcoma (Phase 2)
Lung Neoplasms (Phase 3)
Lymphoma (Phase 3)
Lymphoma, Non-Hodgkin (Phase 3)
Malnutrition (Phase 2)
Melanoma (Phase 3)
Meningioma (Phase 2)
Microsatellite Instability (Phase 2)
Neoplasm Metastasis (Phase 2)
Neoplasms (Phase 3)
Neoplasms, Germ Cell and Embryonal (Phase 3)
Neoplastic Cells, Circulating (Phase 2)
Nervous System Neoplasms (Phase 2)
Oropharyngeal Neoplasms (Phase 3)
Osteosarcoma (Phase 3)
Ovarian Neoplasms (Phase 3)
Pancreatic Neoplasms (Phase 3)
Penile Neoplasms (Phase 2)
Peripheral Nervous System Diseases (Phase 2)
Peritoneal Neoplasms (Phase 3)
Prostatic Neoplasms (Phase 3)
Rectal Neoplasms (Phase 3)
Recurrence (Phase 3)
Salivary Gland Neoplasms (Phase 2)
Sarcoma (Phase 2)
Sarcoma, Ewing (Phase 2)
Seminoma (Phase 3)
Skin Neoplasms (Phase 2)
Small Cell Lung Carcinoma (Phase 3)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Stomach Neoplasms (Phase 3)
Teratoma (Phase 3)
Testicular Neoplasms (Phase 3)
Thyroid Neoplasms (Phase 2)
Ureteral Neoplasms (Phase 2)
Urethral Neoplasms (Phase 2)
Urinary Bladder Neoplasms (Phase 3)
Uterine Cervical Neoplasms (Phase 2)
Uveal Neoplasms (Phase 3)
Vulvar Neoplasms (Phase 2)
